Relmada Therapeutics, Inc.
$7.37
▼
-1.55%
2026-04-21 09:10:01
www.relmada.com
NCM: RLMD
Explore Relmada Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$773.03 M
Current Price
$7.37
52W High / Low
$7.94 / $0.27
Stock P/E
—
Book Value
$1.18
Dividend Yield
—
ROCE
-67.49%
ROE
-25.62%
Face Value
—
EPS
$-1.45
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
—
Debt / Equity
0.1
Current Ratio
80.21
Quick Ratio
14.62
Forward P/E
-17.78
Price / Sales
—
Enterprise Value
$-33.27 M
EV / EBITDA
2.4
EV / Revenue
—
Rating
None
Target Price
$12.8
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tarsus Pharmaceuticals, Inc. | $65.97 | — | $2.86 B | — | -16.64% | -23.39% | $85.25 / $38.51 | $8.07 |
| 2. | Hoth Therapeutics, Inc. | $0.74 | — | $13.96 M | — | -200.97% | -1.91% | $2.12 / $0.49 | $0.4 |
| 3. | Olema Pharmaceuticals, Inc. | $16.58 | — | $1.47 B | — | -37.1% | -36.61% | $36.26 / $3.89 | $5.88 |
| 4. | Design Therapeutics, Inc. | $13.16 | — | $809.14 M | — | -37.28% | -30.7% | $13.5 / $3.1 | $3.52 |
| 5. | Minerva Neurosciences, Inc. | $6.89 | — | $289.51 M | — | -15.79% | 352.58% | $12.46 / $1.3 | $-3.25 |
| 6. | Alaunos Therapeutics, Inc. | $2.84 | — | $6.71 M | — | -233.25% | -1.98% | $6.2 / $1.67 | $1.27 |
| 7. | Ernexa Therapeutics Inc. | $0.19 | — | $5.87 M | 0.34% | -342.48% | -6.87% | $4.05 / $0.18 | $0.31 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -20.33 M | -10.33 M | -10.22 M | -18.22 M | -19.08 M | — |
| Net Profit | -19.87 M | -10.09 M | -9.87 M | -17.56 M | -18.66 M | — |
| EPS in Rs | -0.19 | -0.1 | -0.09 | -0.17 | -0.18 | -0.72 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -59.1 M | -83.89 M | -103.7 M | -161.25 M |
| Net Profit | -57.39 M | -79.98 M | -98.79 M | -157.04 M |
| EPS in Rs | -0.55 | -0.76 | -0.94 | -1.5 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 94 M | 45.82 M | 97.55 M | 152.91 M |
| Total Liabilities | 7.49 M | 10.3 M | 12.19 M | 12.47 M |
| Equity | 86.51 M | 35.52 M | 85.36 M | 140.44 M |
| Current Assets | 93.98 M | 45.8 M | 97.51 M | 152.87 M |
| Current Liabilities | 6.43 M | 10.29 M | 12.19 M | 12.47 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -45.79 M | -51.76 M | -51.66 M | -103.8 M |
| Investing CF | -48.14 M | 51.56 M | 50.45 M | 19.73 M |
| Financing CF | 93.56 M | -0.04 M | -0.1 M | 45.02 M |
| Free CF | -45.79 M | -51.76 M | -51.66 M | -103.8 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 19.04% | 37.09% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.